ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Active-controlled vaccine A

Its studies are mostly in Herpes Zoster, led by Sinovac Biotech.

Furthest: phase 2, since Jan 26, 20261 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech11 open or runningphase 2since Jan 26, 2026Jan 26, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2026First study: phase 2 study in Herpes ZosterFirst studyNCT07400003 · 519 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Active-controlled vaccine A”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07400003Herpes Zoster · China2RecruitingMay 31, 2026519

How it is read

Names in the registry

  • “Active-controlled vaccine A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.